December 17, 2015 / 9:35 AM / 2 years ago

BRIEF-AstraZeneca sees Acerta drug superior to AbbVie/J&J's Imbruvica

Dec 17 (Reuters) - AstraZeneca Plc tells reporters in conference call:

* Executive says Acerta drug more specific than AbbVie/J&J drug, leading to better side effect profile; also hits target harder, which may well translate into better efficacy

* CEO says no comment on pricing plans for Acerta cancer drug

* Ceo says Acerta drug sales will be additional to $45 billion group sales forecast for 2023 announced last year

* Ceo says acquiring Acerta stake was a competitive process

* Ceo says Acerta completes transformation in oncology, wouldn't expect many more cancer deals Further company coverage: (Reporting by UK bureau)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below